Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin, China.
Jpn J Clin Oncol. 2012 Jun;42(6):471-6. doi: 10.1093/jjco/hys046. Epub 2012 Apr 3.
To analyze the clinicopathological features and prognosis of T1mic, a, bN0M0 breast cancer.
The clinical data and survival status of 4487 cases of operable breast cancer treated in our hospital from 2002 to 2005 were collected, including 372 cases with T1mic, a, bN0M0 breast cancers. These patients were divided into four subtypes: Luminal A, Luminal B, triple-negative and human epidermal growth factor receptor 2-positive. Disease-free survival and risk factors for recurrence were identified.
We identified 372 eligible patients. The median follow-up was 78 months (range: 5-106 months). Univariate analysis showed age, adjuvant endocrine therapy, hormonal receptor and human epidermal growth factor receptor 2 were prognostic factors. Multivariate analysis showed that hormonal receptor and human epidermal growth factor receptor 2 were prognostic factors. In the hormonal receptor-positive group, human epidermal growth factor receptor 2-positive patients (Luminal B) had a four times higher recurrence risk than human epidermal growth factor receptor 2 negative (Luminal A) patients. However, there was no statistically significant difference between hormonal receptor-negative groups (triple-negative and human epidermal growth factor receptor 2-positive).
Hormonal receptor and human epidermal growth factor receptor 2 were independent factors of 5-year disease-free survival for patients with T1mic, a, bN0M0 breast cancer. The Luminal B group had a worse prognosis than the Luminal A group, but there was no statistically significant difference between triple-negative and human epidermal growth factor receptor 2-positive groups.
分析 T1mic、a、bN0M0 乳腺癌的临床病理特征和预后。
收集我院 2002 年至 2005 年治疗的 4487 例可手术乳腺癌患者的临床资料和生存状况，其中 T1mic、a、bN0M0 乳腺癌 372 例。将这些患者分为四型：Luminal A、Luminal B、三阴性和人表皮生长因子受体 2 阳性。识别无病生存率和复发风险因素。
我们确定了 372 例合格患者。中位随访时间为 78 个月（范围：5-106 个月）。单因素分析显示年龄、辅助内分泌治疗、激素受体和人表皮生长因子受体 2 是预后因素。多因素分析表明激素受体和人表皮生长因子受体 2 是预后因素。在激素受体阳性组中，人表皮生长因子受体 2 阳性（Luminal B）患者的复发风险比人表皮生长因子受体 2 阴性（Luminal A）患者高四倍。然而，在激素受体阴性组（三阴性和人表皮生长因子受体 2 阳性）中，两者之间无统计学差异。
激素受体和人表皮生长因子受体 2 是 T1mic、a、bN0M0 乳腺癌患者 5 年无病生存率的独立因素。Luminal B 组预后较 Luminal A 组差，但与三阴性和人表皮生长因子受体 2 阳性组无统计学差异。
